




**Figure S1 Analysis of off-site target candidates at predicted sites in the Syrian hamster genome.** A: PCR products flanking each predicted off-target (OT) site (#1–6) in WT and mutant founder hamster; B: PCR product sequencing confirmed no off-target cleavage. Representative sequencing analysis of founder is shown.



**Figure S2 ZZU001 hamsters survival analysis.** ZZU001 Syrian hamsters survive for over 72 weeks (1.5 years). The median survival time exceeds 89 weeks (n=5/group).



**Figure S3 RT-qPCR analysis of lymphocyte-specific genes expression in thymus and bone marrow.** A, B: Lower levels of mRNAs for T, B, NK lymphocyte-specific genes were detected. The amount of the indicated transcripts in thymus homogenates and bone marrow was determined by RT-qPCR using the  $2^{\Delta\Delta Ct}$  method. n=3. <sup>a</sup>P<0.05, <sup>b</sup>P<0.01, <sup>c</sup>P<0.001.



**Figure S4 Flow cytometric analysis of cell populations isolated from thymus and spleen in WT and ZTU001 hamsters.** A, B: CD3<sup>+</sup> and CD4<sup>+</sup> were absent from ZTU001 hamster thymus and spleen. MHC Class II cells were absent from ZTU001 hamster spleen. <sup>a</sup>P<0.05, <sup>b</sup>P<0.01. n=3.



**Table S 1. List of PCR primers used in the study**

Category	Name	Sequence (5`-3`)	Note
For designat ed target	GH IL2RG-F	GAGAGTGGTTCAGGGTCTGACA	For sgRNA/Ca s9-IL2RG
	GH IL2RG-R	TGGGCTGGAGCTCAGAACTG	For sgRNA/Ca s9-IL2RG
For RT- qPCR	GH IL2RGqpc r-F	GAACCCTAGATTTCCCTGCC	
	GH IL2RGqpc r-R	GTATGACTCCCCCAGTGAAC	
For potential off-site targets	OT1F	ACCCAGGACCTCAAGCATGC	
	OT1R	TGACCTGAGTCGATTCCCC	
	OT2F	TGGAAGCAGTGACCAGGCTC	
	OT2R	GGGACCTCATTAGCCTGGAG	
	OT3F	CTCCAGATTCTAAGATTAGCAAT	
		GACA	
	OT3R	TAAGAGTGACTTGTGTGGCCTGA	
		A	
	OT4F	GTCTGGCATCTAATTGCAAAGCA	
	OT4R	CAGAATGAATACTCAAGGAAAT	
		TGCG	
	OT5F	ATGATGGCATAAGATCTGGG	
	OT5R	ACTGGATCACAGGTTTAGG	
	OT6F	GCTTCTGTTTCTGGCCAAG	
	OT6R	GCATCGTATTCTGGTTCAAG	

**Table S 2. Production of IL2RG targeted Syrian hamsters by PN injection**

PN injected	Recipient	Delivery	Total pups	No. Positive pups (%)
181	7	2	8	3 (37.5)

**Table S3. Top six potential off-targets by sgRNA/Cas9-IL2RG**

	Off-targets Sequence (5`-3`)	PA M	Off-target et Scor e	Sequence ID	Location n of sites
OT 1	TAGCAGCTGAAGCAGTA AGA	GA G	3.9	<a href="#">NW_00480161</a> <a href="#">4.1</a>	218259 82 to 218260 04
OT 2	GAAGAGCTGCAGGAGTA AGA	AG G	2.5	<a href="#">NW_00480176</a> <a href="#">3.1</a>	250145 0 to 250147 2
OT 3	CACCAGGTGAAGGAGTA AGA	TG G	1.8	<a href="#">NW_00480171</a> <a href="#">1.1</a>	121582 3 to 121584 5
OT 4	GACCAGCCAAAGGAGTA AGA	CA G	1.6	<a href="#">NW_00480160</a> <a href="#">6.1</a>	243821 63 to 243821 85
OT 5	GATAAGCTGAGGGAGTA AGA	GA G	1.6	<a href="#">NW_00480160</a> <a href="#">4.1</a>	661709 38 to 661709 60
OT 6	GGCCGCTGAATGAGTA AGA	GG G	1.5	<a href="#">NW_00480165</a> <a href="#">4.1</a>	512043 7 to 512045 9

Nucleotide mismatches between the target sequence and the potential off-target sequences are in red letters. Our scoring calculation follows the [Zhang](#)

[Lab's method](#). Score is from 0-100. We include off-target matches for NAG and NGG since both have measurable efficiency.